Literature DB >> 11462043

Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes.

S Duensing1, A Duensing, E R Flores, A Do, P F Lambert, K Münger.   

Abstract

Primary human keratinocytes with ectopic expression of high-risk human papillomavirus (HPV) E6 and E7 oncoproteins display abnormal centrosome numbers, multipolar mitoses, and aneusomy. However, it has not been explored whether these abnormalities can occur in cells containing HPV episomes where E6 and E7 expression is under viral transcriptional control. Here, we demonstrate that centrosome abnormalities and genomic instability occur in organotypic raft cultures of human keratinocytes with episomal HPV-16 even at low copy numbers. We conclude that HPV-16 DNA, when maintained as an episome, can disturb centrosome homeostasis and subvert genomic integrity of the host cell during early stages of the viral infection.

Entities:  

Mesh:

Year:  2001        PMID: 11462043      PMCID: PMC115006          DOI: 10.1128/JVI.75.16.7712-7716.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Induction of chromosome abnormalities in mouse and human epidermal keratinocytes by the human papillomavirus type 16 E7 oncogene.

Authors:  T Hashida; S Yasumoto
Journal:  J Gen Virol       Date:  1991-07       Impact factor: 3.891

2.  Definition of precursors.

Authors:  Y S Fu; J W Reagan; R M Richart
Journal:  Gynecol Oncol       Date:  1981-10       Impact factor: 5.482

3.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

4.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

5.  The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle.

Authors:  S Duensing; L Y Lee; A Duensing; J Basile; S Piboonniyom; S Gonzalez; C P Crum; K Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype.

Authors:  S Duensing; A Duensing; C P Crum; K Münger
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

7.  Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells.

Authors:  S Jeon; B L Allen-Hoffmann; P F Lambert
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Human papillomavirus type 16 and early cervical neoplasia.

Authors:  C P Crum; H Ikenberg; R M Richart; L Gissman
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

Review 9.  Viruses in human cancers.

Authors:  H zur Hausen
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

10.  Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins.

Authors:  A E White; E M Livanos; T D Tlsty
Journal:  Genes Dev       Date:  1994-03-15       Impact factor: 11.361

View more
  37 in total

Review 1.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 2.  Genomic instability and cancer: lessons learned from human papillomaviruses.

Authors:  Nina Korzeniewski; Nicole Spardy; Anette Duensing; Stefan Duensing
Journal:  Cancer Lett       Date:  2010-11-13       Impact factor: 8.679

3.  Role of the E1--E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31.

Authors:  Regina Wilson; Frauke Fehrmann; Laimonis A Laimins
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Amplification of the chromosome 20q region is associated with expression of HPV-16 E7 in human airway and anogenital epithelial cells.

Authors:  Aloysius J Klingelhutz; Qining Qian; Stacia L Phillips; Francoise A Gourronc; Benjamin W Darbro; Shivanand R Patil
Journal:  Virology       Date:  2005-09-30       Impact factor: 3.616

Review 5.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

Review 6.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

7.  Examination of the pRb-dependent and pRb-independent functions of E7 in vivo.

Authors:  Scott Balsitis; Fred Dick; Denis Lee; Linda Farrell; R Katherine Hyde; Anne E Griep; Nicholas Dyson; Paul F Lambert
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Chromosomal aberrations accumulate in polyploid cells of high-grade squamous intraepithelial lesions (HSIL).

Authors:  Gábor Méhes; Norbert Speich; Magdolna Bollmann; Reinhard Bollmann
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

9.  High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer.

Authors:  Peng Gao; Jie Zheng
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

10.  The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells.

Authors:  Nicole Spardy; Anette Duensing; Domonique Charles; Nathan Haines; Tomomi Nakahara; Paul F Lambert; Stefan Duensing
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.